Møller Søren, Henriksen Jens H, Bendtsen Flemming
Department of Clinical Physiology 239, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Hvidovre, Denmark.
Scand J Gastroenterol. 2009;44(8):902-11. doi: 10.1080/00365520902912555.
Ascites is a classic complication of advanced cirrhosis and it often marks the first sign of hepatic decompensation. Ascites occurs in more than 50% of patients with cirrhosis, worsens the course of the disease, and reduces survival substantially. Portal hypertension, splanchnic vasodilatation, liver insufficiency, and cardiovascular dysfunction are major pathophysiological hallmarks. Modern treatment of ascites is based on this recognition and includes modest salt restriction and stepwise diuretic therapy with spironolactone and loop-diuretics. Tense and refractory ascites should be treated with large volume paracentesis followed by plasma volume expansion or transjugular intrahepatic portosystemic shunt. Ascites complicated by spontaneous bacterial peritonitis requires adequate treatment with antibiotics. New potential treatment strategies include the use of vasopressin V(2)-receptor antagonists and vasoconstrictors. Since formation of ascites is associated with a poor prognosis, and treatment of fluid retention does not substantially improve survival, such patients should always be considered for liver transplantation.
腹水是晚期肝硬化的典型并发症,常标志着肝失代偿的首个征象。超过50%的肝硬化患者会出现腹水,它会使疾病进程恶化,并显著降低生存率。门静脉高压、内脏血管扩张、肝功能不全和心血管功能障碍是主要的病理生理特征。现代腹水治疗基于这一认识,包括适度限盐以及使用螺内酯和襻利尿剂进行逐步利尿治疗。张力性和难治性腹水应采用大量腹腔穿刺放液,随后进行血浆容量扩充或经颈静脉肝内门体分流术治疗。并发自发性细菌性腹膜炎的腹水需要使用抗生素进行充分治疗。新的潜在治疗策略包括使用血管加压素V(2)受体拮抗剂和血管收缩剂。由于腹水的形成与预后不良相关,且液体潴留的治疗并不能显著提高生存率,因此这类患者应始终考虑进行肝移植。